Ulrika Axcrona

1.5k total citations · 2 hit papers
32 papers, 726 citations indexed

About

Ulrika Axcrona is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Surgery. According to data from OpenAlex, Ulrika Axcrona has authored 32 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 10 papers in Cancer Research and 9 papers in Surgery. Recurrent topics in Ulrika Axcrona's work include Prostate Cancer Treatment and Research (21 papers), Prostate Cancer Diagnosis and Treatment (17 papers) and Cancer, Lipids, and Metabolism (6 papers). Ulrika Axcrona is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Prostate Cancer Diagnosis and Treatment (17 papers) and Cancer, Lipids, and Metabolism (6 papers). Ulrika Axcrona collaborates with scholars based in Norway, Sweden and Germany. Ulrika Axcrona's co-authors include Karol Axcrona, Rolf I. Skotheim, Ragnhild A. Lothe, Ljiljana Vlatkovic, Anne Cathrine Bakken, Ali Khatami, Andreas Socratous, Jonas Hugosson, Johan Stranne and Jonas Wallström and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ulrika Axcrona

32 papers receiving 723 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only

2022 176 citations Jonas Hugosson, Marianne Månsson et al. New England Journal of Medicine profile →
Results after Four Years of Screening for Prostate Cancer with PSA and MRI

2024 35 citations Jonas Hugosson, Rebecka Arnsrud Godtman et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Ulrika Axcrona

Since Specialization

Citations

This map shows the geographic impact of Ulrika Axcrona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrika Axcrona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrika Axcrona more than expected).

Fields of papers citing papers by Ulrika Axcrona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrika Axcrona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrika Axcrona. The network helps show where Ulrika Axcrona may publish in the future.

Co-authorship network of co-authors of Ulrika Axcrona

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrika Axcrona. A scholar is included among the top collaborators of Ulrika Axcrona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrika Axcrona. Ulrika Axcrona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer 2024 ·Neoplasia ·(unknown), (unknown), (unknown), Bjarne Johannessen, Anne Cathrine Bakken, Ragnhild A. Lothe, Karol Axcrona, Rolf I. Skotheim, Ulrika Axcrona	1
2	Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature 2024 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Rolf I. Skotheim, (unknown), (unknown), Ulrika Axcrona, Karol Axcrona	9
3	Results after Four Years of Screening for Prostate Cancer with PSA and MRI breakdown → 2024 ·New England Journal of Medicine ·Jonas Hugosson, Rebecka Arnsrud Godtman, Jonas Wallström, Ulrika Axcrona, Anders Bergh, Lars Egevad, Kjell Geterud, Ali Khatami, Andreas Socratous, (unknown), Linda Svensson, Johan Stranne, Marianne Månsson, Mikael Hellström	35
4	Multi-parametric MRI without artificial erection for preoperative assessment of primary penile carcinoma: A pilot study on the correlation between imaging and histopathological findings 2023 ·European Journal of Radiology Open ·(unknown), (unknown), (unknown), Bjørn Brennhovd, (unknown), (unknown), Ulrika Axcrona, Knut Håkon Hole	5
5	‘High proliferative cribriform prostate cancer’ defines a patient subgroup with an inferior prognosis 2023 ·Histopathology ·(unknown), Rolf I. Skotheim, (unknown), (unknown), Ragnhild A. Lothe, Karol Axcrona, Ulrika Axcrona	4
6	Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer 2022 ·International Journal of Cancer ·(unknown), Bjarne Johannessen, (unknown), Anne Cathrine Bakken, (unknown), Andreas Hoff, Ulrika Axcrona, Karol Axcrona, Ragnhild A. Lothe, Rolf I. Skotheim	4
7	Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity 2022 ·Cancer Gene Therapy ·(unknown), Bjarne Johannessen, (unknown), (unknown), (unknown), Xiaokang Zhang, Anita Sveen, Anthony Mathelier, Ragnhild A. Lothe, Ulrika Axcrona, Karol Axcrona, Rolf I. Skotheim	6
8	In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis 2022 ·Molecular Oncology ·(unknown), (unknown), (unknown), Anne Cathrine Bakken, (unknown), Marthe Løvf, Ragnhild A. Lothe, Karol Axcrona, Ulrika Axcrona, Rolf I. Skotheim	5
9	Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only breakdown → 2022 ·New England Journal of Medicine ·Jonas Hugosson, Marianne Månsson, Jonas Wallström, Ulrika Axcrona, Sigrid Carlsson, Lars Egevad, Kjell Geterud, Ali Khatami, Kimia Kohestani, Carl‐Gustaf Pihl, Andreas Socratous, Johan Stranne, Rebecka Arnsrud Godtman, Mikael Hellström	176
10	High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity 2021 ·Neoplasia ·(unknown), (unknown), (unknown), (unknown), Anne Cathrine Bakken, Marthe Løvf, Ragnhild A. Lothe, Karol Axcrona, Ulrika Axcrona, Rolf I. Skotheim	23
11	Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma 2020 ·Annals of Diagnostic Pathology ·Leili Saeednejad Zanjani, Zahra Madjd, Ulrika Axcrona, Maryam Abolhasani, Arezoo Rasti, Mojgan Asgari, Øystein Fodstad, Yvonne Andersson	28
12	Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity 2018 ·European Urology ·Marthe Løvf, Sen Zhao, Ulrika Axcrona, Bjarne Johannessen, Anne Cathrine Bakken, (unknown), Andreas Hoff, Ola Myklebost, Leonardo A. Meza‐Zepeda, A. Kathrine Lie, Karol Axcrona, Ragnhild A. Lothe, Rolf I. Skotheim	110
13	Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway 2017 ·Urology ·(unknown), Karol Axcrona, Rune Kvåle, Bjørn Møller, Tor Åge Myklebust, Ulrika Axcrona, Viktor Berge, Sophie D. Fosså	8
14	Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study 2017 ·OncoTargets and Therapy ·Christian Beisland, T.B. Johannesen, Olbjørn Klepp, Ulrika Axcrona, Knut Martin Torgersen, Jan Kowalski, Oddvar Solli, Rickard Sandin, Jan Oldenburg	27
15	Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery 2017 ·Cytotherapy ·(unknown), Iris Bigalke, Karol Axcrona, Else Marit Inderberg, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dag Josefsen, Ulrika Axcrona, Steinar Aamdal, Wolfgang Lilleby, Bjørn Brennhovd, Svein Dueland, Gunnar Kvalheim	1
16	Exome Sequencing of Bilateral Testicular Germ Cell Tumors Suggests Independent Development Lineages 2015 ·Neoplasia ·(unknown), Bjarne Johannessen, Ulrika Axcrona, Sigrid Marie Kraggerud, (unknown), Anne Cathrine Bakken, Jarle Bruun, Sophie D. Fosså, Ragnhild A. Lothe, Gustav Lehne, Rolf I. Skotheim	8
17	The Length of a Positive Surgical Margin Is of Prognostic Significance in Patients with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy 2014 ·Urologia Internationalis ·(unknown), Ljiljana Vlatkovic, (unknown), Jahn M. Nesland, Ulrika Axcrona, (unknown), Karol Axcrona	24
18	Blocking mtDNA Replication Upregulates the Expression of Stemness-related Genes in Prostate Cancer Cell Lines 2013 ·Ultrastructural Pathology ·(unknown), Xueping Wu, Xiaoran Li, Gunnar Kvalheim, Ulrika Axcrona, Karol Axcrona, Zhenhe Suo	3
19	Expression pattern of adhesion molecules (E‐cadherin, α‐, β‐, γ‐catenin and claudin‐7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis 2007 ·Apmis ·Daehoon Park, Rolf Kåresen, Ulrika Axcrona, (unknown), Torill Sauer	56
20	Islet neuronal abnormalities associated with impaired insulin secretion in type 2 diabetes in the Chinese hamster 1999 ·Regulatory Peptides ·К.-D. Kohnert, Ulrika Axcrona, B Hehmke, Ingrid Klöting, F. Sundler, Bo Åhrén	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact